ACE-tRNA Stop Codon Reassignment for Full-Length Protein Rescue

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Nonsense mutations in DNA that convert amino acid-encoding codons to stop codons result in truncated proteins, leading to genetic diseases like cystic fibrosis, muscular dystrophy, and β-thalassemia, as current therapies like PTC124 and aminoglycosides are inefficient and have limitations.

Innovation Solution

Development of modified transfer RNAs (tRNAs) with altered anticodons that recognize stop codons and deliver specific amino acids, enhancing interaction with Elongation Factor 1-alpha to stabilize and promote continued protein translation, using vectors for delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nonsense suppressor tRNAs are used to suppress stop codons, then full-length protein production is restored, but the suppression efficiency is insufficient and therapeutic outcomes are limited

Engineering Contradiction:

Improvenonsense suppression efficiencyVSAvoidfull-length protein production

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the tRNA molecule by changing parameters such as the anticodon sequence to recognize different stop codons (UAA, UAG, UGA), modifying the T-stem region to enhance stability and EF1α interaction, and adjusting other structural parameters to optimize suppression efficiency. These parameter changes enable the tRNA to effectively suppress nonsense mutations while maintaining high suppression efficiency.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite functional system combining modified tRNA molecules with specific amino acids and elongation factors. The modified tRNA structure integrates multiple functional elements: the anticodon arm for stop codon recognition, the acceptor arm for amino acid attachment, and the modified T-stem for enhanced stability and ribosomal interaction, forming a composite molecular machine that achieves high-efficiency nonsense suppression.

Inventive Principle:

Principle #40Composite materials

2Reliability

If current therapies like PTC124 and aminoglycosides are used, then stop codon suppression is achieved, but the therapies are inefficient and have limitations

Engineering Contradiction:

Improvestop codon suppressionVSAvoidtherapeutic efficiency

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The modified tRNA system is self-sufficient and does not require external chemical compounds or complex delivery systems. The tRNA molecule itself carries the suppression function through its modified structure, and the cell's natural translation machinery (ribosomes, elongation factors) performs the suppression action. This self-service mechanism eliminates the need for inefficient external drugs like PTC124 or aminoglycosides.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent replaces the chemical mechanism of existing therapies (PTC124 binding to ribosome, aminoglycoside interference with translation) with a biological mechanism using modified tRNAs. The modified tRNA directly interacts with the ribosome through its anticodon and T-stem regions, substituting the need for chemical drug molecules and providing a more efficient and targeted suppression mechanism.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified tRNAs effectively suppress stop codons, restoring full-length protein production and improving therapeutic outcomes for genetic diseases by increasing nonsense suppression activity.

Implementation Method 1

Each tRNA contains an 'anti-codon' region that hybridizes with a complementary codon on the mRNA

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

the T-stem comprises nucleotides that interact with Elongation Factor 1-alpha 1 (EF1alpha). EF1alpha recruits aminoacyl-tRNA to the ribosome and protects the tRNA from being deacylated

Methodology Applied

Scientific EffectProtein-RNA interaction:

Data Source

PatentUS12565649B2Methods of rescuing stop codons via genetic reassignment with ACE-tRNA

Publication Date: 2026.03.03 THE UNIVERSITY OF IOWA RESEARCH

AI summary

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.